BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

MYOS Files Patent for MYO-T12 to Prevent Muscle Loss


10/15/2012 9:09:54 AM

CEDAR KNOLLS, NJ--(Marketwire - October 15, 2012) -

MYOS Corporation (OTCBB: MYOS), a company focused on the discovery, development and commercialization of therapeutic products that improve muscle health and performance, announced today the filing of a new patent application to help prevent or ameliorate the loss of lean muscle mass in both normal and chronically ill individuals with the use of MYO-T12®.

MYOS believes that its leading product MYO-T12 is the first dietary supplement of its kind. MYO-T12 reversibly suppresses the activity of myostatin, a natural regulatory protein which inhibits the growth and proliferation of muscle cells in response to exercise or injury. MYOS is committed to its on-going research evaluating the therapeutic uses and benefits of this dietary supplement and is looking forward to publishing the results of this work in the future.

"Patent counsel Jura Zibas of the national law firm Wilson Elser commented, "MYOS Corporation's growing portfolio of patents will be central to the future of the company, which is focused on improving health and performance of the vitally important muscular system."

Peter Levy, Chief Operating Officer of MYOS, said, "Advancing earlier-stage research programs is essential to ensuring sustained long-term growth and development of our intellectual property portfolio and life cycle management of these important assets. We are hopeful that these efforts create additional innovative intellectual property, enhancing value for our company and our stakeholders, and making MYOS more attractive to the investor community."

About MYOS Corporation

MYOS is a development stage company focused on the discovery, development and commercialization of therapeutic products that improve muscle health and performance. MYOS is the owner of MYO-T12, the world's first clinically demonstrated myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. MYO-T12 is manufactured to optimize biological activity, which MYOS believes has the potential to redefine existing standards of physical health and wellness enhancement. For more information on MYO-T12 and to discover why MYOS is known as "The Muscle Company,"™ visit www.myoscorp.com.

Forward-Looking Statements

Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.


Contact:
Investor Contact
CEOcast, Inc.
Bob Woods
212-732-4300
Investor Relations
Email Contact

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES